歌礼制药(01672.HK)料第三季向美国药监局递交ASC39口服片治疗肥胖症IND

阿斯达克财经
Yesterday

歌礼制药(01672.HK) 公布,已选定对胰淀素具有选择性的强效口服小分子胰淀素受体激动剂ASC39作为临床开发候选药物,预计将于2026年第三季度向美国食品药品监督管理局(FDA)递交ASC39口服片治疗肥胖症的新药临床试验申请(IND)。ASC39是一种对胰淀素具有选择性的强效口服小分子胰淀素受体激动剂,正在既作为单药开发,也作为与ASC30联用(ASC30为歌礼口服小分子、已具备III期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10